Aclaris Therapeutics (ACRS) Profit After Tax: 2017-2025
Historic Profit After Tax for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$14.6 million.
- Aclaris Therapeutics' Profit After Tax fell 92.64% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.7 million, marking a year-over-year decrease of 282.88%. This contributed to the annual value of -$132.1 million for FY2024, which is 49.26% down from last year.
- As of Q3 2025, Aclaris Therapeutics' Profit After Tax stood at -$14.6 million, which was up 5.28% from -$15.4 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Profit After Tax peaked at -$1.5 million during Q4 2023, and registered a low of -$96.6 million during Q4 2024.
- Its 3-year average for Profit After Tax is -$24.2 million, with a median of -$15.4 million in 2025.
- In the last 5 years, Aclaris Therapeutics' Profit After Tax surged by 94.60% in 2023 and then tumbled by 6,375.65% in 2024.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' Profit After Tax stood at -$22.8 million in 2021, then declined by 21.18% to -$27.6 million in 2022, then soared by 94.60% to -$1.5 million in 2023, then tumbled by 6,375.65% to -$96.6 million in 2024, then plummeted by 92.64% to -$14.6 million in 2025.
- Its Profit After Tax was -$14.6 million in Q3 2025, compared to -$15.4 million in Q2 2025 and -$15.1 million in Q1 2025.